Skip to main content
TipRanks
Go Ultimate75% OFF

Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis

0 Followers
SE:CLS.B

Clinical Laserthermia Systems AB Class B

(Nasdaq OMX AB:CLS.B)

Select Model
Rating:42Neutral
Price Target:SEK 1.50â–¼(-5.54% Downside)
Action:upgraded
Date:11/21/26

Clinical Laserthermia Systems AB presents a highly speculative and weak investment profile, primarily driven by significant operational losses, shrinking revenues, and a stark bearish technical trend. While a pristine, zero-debt balance sheet provides crucial short-term stability and liquidity, the lack of profitability, persistent negative cash flow, and deeply depressed valuation heavily suppress the overall score.

Positive Factors
Revenue GrowthTTM revenue growth of approximately 17.7% shows that demand and commercial scale have expanded despite the company’s current losses. Continued top-line progress can broaden the installed base, support recurring procedure-related revenue, and create operating leverage if gross margins improve.
Negative Factors
Negative Gross ProfitNegative gross profit means current revenue is not covering direct costs, while deeply negative EBIT and EBITDA margins show that operating expenses remain far above the business’s earnings capacity. This weakens margin sustainability and makes profitable scaling dependent on substantial improvement.

Clinical Laserthermia Systems AB Class B (CLS.B) vs. iShares MSCI Sweden ETF (EWD)

-80%-60%-40%-20%0%20%40%SE:CLS.B-77.68%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 77.04M
Dividend Yield
―
Average Volume (3M)
72.79K
Price to Earnings (P/E)
-1.4
Beta (1Y)
0.38
Revenue Growth
-30.50%
EPS Growth
34.34%
Country
Sweden
Employees
13
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company Description

Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The...

How the Company Makes Money

CLS generates revenue primarily from selling its laser ablation/thermotherapy platform and associated consumables used in clinical procedures. Key revenue streams typically include: (1) system/platform sales (capital equipment) to hospitals and clini...

Clinical Laserthermia Systems AB Class B Financial Statement Overview

Summary

Financial performance is heavily weighed down by contracting revenues (declining to 14.78M TTM), deeply negative gross margins, and persistent cash burn. However, the company maintains a pristine, zero-debt balance sheet with 83.14M in total assets, which insulates it from immediate solvency risks.

Income Statement

20Very Negative

Balance Sheet

85Very Positive

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue14.78M17.49M18.78M8.27M6.27M2.25M
Gross Profit-12.33M-29.00M10.42M3.00M-2.79M-3.63M
EBITDA-36.63M-26.41M-44.76M-68.41M-57.84M-57.05M
Net Income-36.77M-41.61M-47.62M-79.79M-70.66M-63.62M
Balance Sheet
Total Assets83.15M76.49M78.56M57.73M49.51M66.74M
Cash, Cash Equivalents and Short-Term Investments23.19M21.55M22.51M15.33M10.59M31.17M
Total Debt00224.00K454.00K30.68M273.50K
Total Liabilities18.64M10.00M12.88M14.20M41.64M45.55M
Stockholders Equity67.98M69.67M68.72M45.77M9.22M21.79M
Cash Flow
Free Cash Flow-36.99M-36.00M-58.92M-71.95M-71.25M-66.73M
Operating Cash Flow-29.64M-33.20M-56.45M-66.45M-70.69M-66.17M
Investing Cash Flow-7.35M-2.80M-7.47M-5.50M-886.00K-408.00K
Financing Cash Flow46.98M35.04M71.10M76.69M61.84M85.88M

Clinical Laserthermia Systems AB Class B Technical Analysis

Technical Analysis SentimentNegative
Last Price1.59

Price Trends

50DMA1.77Negative
100DMA2.01Negative
200DMA3.36Negative

Market Momentum

MACD-0.05Positive
RSI30.28Neutral
STOCH21.76Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Negative. The current price of 1.59 is below the 20-day moving average (MA) of 1.72, below the 50-day MA of 1.77, and below the 200-day MA of 3.36, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 30.28 is Neutral, neither overbought nor oversold. The STOCH value of 21.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLS.B.

Clinical Laserthermia Systems AB Class B Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:CLS.B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:RAY.BSE:RAY.B63NeutralSEK 5.87B28.0122.61%2.37%3.16%-5.78%
SE:PAXSE:PAX58NeutralSEK 1.59B-294.23-1.22%―29.41%-76.41%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:CRAD.BSE:CRAD.B48NeutralSEK 796.90M16.4813.23%0.43%-8.76%103.87%
SE:CLS.BSE:CLS.B42NeutralSEK 77.04M-1.39-59.72%―-30.50%34.34%
SE:SPAGOSE:SPAGO42NeutralSEK 33.21M-1.03-87.37%―-97.52%31.31%
SE:SPECSE:SPEC38UnderperformSEK 19.12M-0.34-25.90%――78.15%

* Healthcare Sector Average

Performance Comparison

-50%0%SE:CLS.BSE:PAXSE:RAY.BSE:SPECSE:CRAD.BSE:SPAGODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:CLS.B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:CLS.BClinical Laserthermia Systems AB Class B1.59-5.54-77.72%
SE:PAXPaxman AB64.208.4015.05%
SE:RAY.BRaySearch Laboratories AB Class B168.60-51.74-23.48%
SE:SPECSpectraCure AB0.01-0.11-89.68%
SE:CRAD.BC-Rad AB Class B23.20-10.80-31.76%
SE:SPAGOSpago Nanomedical AB0.04-0.05-56.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 21, 2026